HGH Fragment 176-191

PRESENTATION

• 5 x 10 mg lyophilized powder vials

• 5 x 2 ml bacteriostatic water vials (for reconstitution)

ACTIVE INGREDIENT

Each vial contains:

• Human Growth Hormone Fragment 176-191 10 mg

DESCRIPTION

HGH Fragment 176-191 is a synthetic peptide derived from the C-terminal end of the human growth hormone (HGH) molecule, specifically residues 176-191. This fragment has been found to retain the fat-burning properties of HGH without impacting growth or increasing insulin resistance. HGH Fragment 176-191 is widely used for its lipolytic (fat-reducing) properties and its ability to support fat metabolism without influencing blood sugar levels.

The product is supplied as a sterile, lyophilized powder for reconstitution prior to administration.

PHARMACOLOGICAL CLASSIFICATION

Lipolytic Peptide

PHARMACOLOGICAL PROPERTIES

Mechanism of Action: HGH Fragment 176-191 mimics the fat-burning activity of the natural human growth hormone by stimulating lipolysis (the breakdown of fats) and inhibiting lipogenesis (the formation of new fat cells). This peptide specifically targets adipose (fat) tissue, enhancing fat reduction while avoiding the typical side effects associated with full-length HGH, such as insulin sensitivity issues.

Pharmacokinetics:

• Absorption: Rapidly absorbed after subcutaneous injection.
• Distribution: Primarily distributed to adipose tissue.
• Metabolism: Metabolized by tissue enzymes.
• Excretion: Excreted via the kidneys.

INDICATIONS

HGH Fragment 176-191 is indicated for:

• Fat Reduction and Weight Loss: To enhance fat metabolism, particularly in stubborn fat areas such as the abdomen.
• Improved Body Composition: Supporting lean body mass maintenance while reducing fat mass.
• Energy Boost: To enhance overall energy levels by improving fat utilization.
• Aiding in Metabolic Health: For users seeking fat reduction without impacting glucose metabolism.

DOSAGE AND ADMINISTRATION

Dosage:

• Standard Dosing: 250 mcg to 500 mcg administered subcutaneously once or twice daily. The most common dosing schedule includes an injection in the morning and one post-exercise or in the evening.
• Duration of Use: It is typically used for 4 to 6 weeks, followed by a break, depending on the therapeutic goals.

Administration:

1. Reconstitute the lyophilized powder with bacteriostatic water.
2. Inject subcutaneously into areas with more fat tissue, such as the abdomen or thigh.
3. Rotate injection sites to avoid irritation or localized fat depletion.

Reconstitution:

• Reconstitute each 10 mg vial with an appropriate amount of bacteriostatic water (1 ml to 2 ml is common).
• Store the reconstituted solution in the refrigerator and use within 7 days.

CONTRAINDICATIONS

• Hypersensitivity: Contraindicated in individuals with known hypersensitivity to HGH Fragment 176-191 or any of its components.
• Pregnancy and Lactation: Not recommended during pregnancy or breastfeeding, as there is insufficient data regarding safety.

WARNINGS AND PRECAUTIONS

1. Diabetic and Pre-diabetic Patients: While HGH Fragment 176-191 has minimal impact on glucose levels, caution should be exercised in individuals with diabetes or pre-diabetes. Monitor blood sugar levels regularly.

2. Cardiovascular Conditions: Patients with cardiovascular issues should consult a healthcare provider before using HGH Fragment 176-191, as it can alter fat metabolism, potentially impacting lipid levels.

3. Long-term Use: Long-term use should be under the supervision of a healthcare professional to prevent any potential side effects or imbalances in metabolic function.

ADVERSE REACTIONS

Common side effects:

• Redness, swelling, or pain at the injection site
• Temporary fatigue or headache
• Dizziness or lightheadedness

Serious adverse effects:

• Allergic Reactions: May cause rash, swelling, or difficulty breathing. Discontinue use and seek medical attention immediately if these occur.
• Muscle or Joint Pain: Some users may experience joint or muscle discomfort.

INTERACTIONS

• Insulin or Antidiabetic Medications: HGH Fragment 176-191 does not directly impact insulin levels, but caution is advised when using alongside insulin or other glucose-regulating medications.
• Steroids and Other Fat-Burning Agents: Using HGH Fragment 176-191 with steroids or other fat-reduction agents may amplify the effects. Monitor for exaggerated fat-loss or related symptoms.

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation: HGH Fragment 176-191 has not been studied in pregnant or lactating women. Its use is not recommended unless prescribed by a healthcare professional.

Pediatric Use: This product is not intended for use in children or adolescents under 18 years of age.

Geriatric Use: Older adults may experience benefits from fat metabolism regulation but should use HGH Fragment 176-191 with caution, particularly if they have metabolic or cardiovascular concerns.

OVERDOSAGE

Overdose of HGH Fragment 176-191 is rare, but if taken in excessive amounts, symptoms such as dizziness, lightheadedness, or abnormal fatigue may occur. If overdose is suspected, discontinue use and seek medical advice.

STORAGE

Store the lyophilized powder at controlled room temperature (20°C to 25°C / 68°F to 77°F).

Once reconstituted, store the solution in the refrigerator at 2°C to 8°C (36°F to 46°F) and use within 7 days.

Do not freeze. Keep out of reach of children.

PACKAGING

HGH Fragment 176-191 is supplied in the following packaging:

• 5 x 10 mg vials of lyophilized powder
• 5 x 2 ml vials of bacteriostatic water

MANUFACTURER

Oxydine Metabolics Switzerland

Oxydine.org
Hi@Oxydine.org